Psychedelics as Psychiatric Medications
Herausgeber: Nutt, David; Castle, David
Psychedelics as Psychiatric Medications
Herausgeber: Nutt, David; Castle, David
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This book provides an overview of this hugely exciting field, covering the history of psychedelics, clinical aspects, risks and side effects, precautions and processes.
Andere Kunden interessierten sich auch für
David J CastleSchizophrenia and Psychiatric Comorbidities41,99 €
Giovanni FavaDiscontinuing Antidepressant Medications47,99 €
Carol NorthGoodwin and Guze's Psychiatric Diagnosis 7th Edition77,99 €
Ali A Asadi-PooyaAntiseizure Medications102,99 €
Psychiatric Genetics84,99 €
Nancy Nyquist PotterVirtue of Defiance and Psychiatric Engagement54,99 €
American Psychiatric AssociationEthics Primer of the American Psychiatric Association48,99 €-
-
-
This book provides an overview of this hugely exciting field, covering the history of psychedelics, clinical aspects, risks and side effects, precautions and processes.
Produktdetails
- Produktdetails
- Verlag: Oxford University Press
- Seitenzahl: 160
- Erscheinungstermin: 30. Juni 2023
- Englisch
- Abmessung: 216mm x 141mm x 17mm
- Gewicht: 217g
- ISBN-13: 9780192863607
- ISBN-10: 0192863606
- Artikelnr.: 67732887
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
- Verlag: Oxford University Press
- Seitenzahl: 160
- Erscheinungstermin: 30. Juni 2023
- Englisch
- Abmessung: 216mm x 141mm x 17mm
- Gewicht: 217g
- ISBN-13: 9780192863607
- ISBN-10: 0192863606
- Artikelnr.: 67732887
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- gpsr@libri.de
David Nutt is a psychiatrist and the Edmond J. Safra Professor of Neuropsychopharmacology in Imperial College London. He is currently Founding Chair of the charity DrugScience.org.uk and has been president of the European Brain Council, the BAP, BNA, and ECNP. David has published 35 books and over 1000 research papers that define his many landmark contributions to psychopharmacology including GABA and noradrenaline receptor function in anxiety disorders, serotonin function in depression, endorphin and dopamine function in addiction and the neuroscience and clinical utility of psychedelics. Some of this has been made into films e.g. on Netflix and on the BBC and a play . He broadcasts widely to the general public on pharmacology and psychiatric matters, has over 60k followers on twitter and has his own very popular podcast... David Castle is Inaugural Scientific Director of the Centre for Complex Interventions (CCI) at the Centre for Addictions and Mental Health (CAMH), Toronto, Canada; and Professor, Department of Psychiatry, The University of Toronto. He has wide clinical and research interests, encompassing schizophrenia and related disorders, bipolar disorder, OCD spectrum disorders and disorders of body image. He has a longstanding interest in the impact of licit and illicit substances on the brain and body, and is actively engaged in a series of trials investigating psychedelics as psychiatric medicines. He has published widely and is a frequent speaker at scientific meetings.
* 1. Historical Overview
* 2. The psychotherapeutic component of psychedelic medicine (includes
set, setting, anticipation, expectancy, preparation, integration)
* 3. Psilocybin
* 4. MDMA
* 5. Lysergic Acid Diethylamid: In Search of the Wonder Drug
* 6. Ayahuasca
* 7. Ibogaine
* 8. Other psychedelics
* 9. Ketamine
* 10. Risks and side effects associated with the use of psychedelics
* 11. Psychedelics as psychiatric medicines: current challenges and
future prospects
* 2. The psychotherapeutic component of psychedelic medicine (includes
set, setting, anticipation, expectancy, preparation, integration)
* 3. Psilocybin
* 4. MDMA
* 5. Lysergic Acid Diethylamid: In Search of the Wonder Drug
* 6. Ayahuasca
* 7. Ibogaine
* 8. Other psychedelics
* 9. Ketamine
* 10. Risks and side effects associated with the use of psychedelics
* 11. Psychedelics as psychiatric medicines: current challenges and
future prospects
* 1. Historical Overview
* 2. The psychotherapeutic component of psychedelic medicine (includes
set, setting, anticipation, expectancy, preparation, integration)
* 3. Psilocybin
* 4. MDMA
* 5. Lysergic Acid Diethylamid: In Search of the Wonder Drug
* 6. Ayahuasca
* 7. Ibogaine
* 8. Other psychedelics
* 9. Ketamine
* 10. Risks and side effects associated with the use of psychedelics
* 11. Psychedelics as psychiatric medicines: current challenges and
future prospects
* 2. The psychotherapeutic component of psychedelic medicine (includes
set, setting, anticipation, expectancy, preparation, integration)
* 3. Psilocybin
* 4. MDMA
* 5. Lysergic Acid Diethylamid: In Search of the Wonder Drug
* 6. Ayahuasca
* 7. Ibogaine
* 8. Other psychedelics
* 9. Ketamine
* 10. Risks and side effects associated with the use of psychedelics
* 11. Psychedelics as psychiatric medicines: current challenges and
future prospects







